Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

A Pilot Trial of Interferon beta-1a in Alzheimer's Disease
A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy.
Focal vibration in neurorehabilitation.
Benign multiple sclerosis: a distinct clinical entity with therapeutic implications.
Treatment of multiple sclerosis with the pregnancy hormone estriol.
Immune competence after alemtuzumab treatment of multiple sclerosis.
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.
Association of Immunotherapies With Outcomes in Relapsing-Remitting Multiple Sclerosis.
New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.
Severe liver dysfunction possibly caused by the combination of interferon beta-1b therapy and melilot (sweet clover) supplement.
Gene expression analysis reveals functional pathways of glatiramer acetate activation.
Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up.
Prevalence of neurological disorders in Al Quseir, Egypt: methodological aspects.
Glatiramer Acetate and Nanny Proteins Restrict Access of the Multiple Sclerosis Autoantigen Myelin Basic Protein to the 26S Proteasome.
A much-needed focus on progression in multiple sclerosis.
Dilantin
Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events.
Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial.
Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study.
T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10.
KIR2DL2 inhibitory pathway enhances Th17 cytokine secretion by NK cells in response to herpesvirus infection in multiple sclerosis patients.
Are natural killer cells involved in multiple sclerosis etiology? Evidences from NKp46/NCR1 receptor modulation in an observational study.
Foxp3(+) Treg cells in the inflamed CNS are insensitive to IL-6-driven IL-17 production.
Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years.

Pages